fullerene c60 has been researched along with imatinib mesylate in 1 studies
| Studies (fullerene c60) | Trials (fullerene c60) | Recent Studies (post-2010) (fullerene c60) | Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) |
|---|---|---|---|---|---|
| 3,806 | 5 | 2,170 | 11,477 | 960 | 5,773 |
| Protein | Taxonomy | fullerene c60 (IC50) | imatinib mesylate (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.31 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Funakoshi-Tago, M; Mashino, T; Nakazawa, Y; Ohe, T; Sumi, K; Tago, K; Takahashi, K | 1 |
1 other study(ies) available for fullerene c60 and imatinib mesylate
| Article | Year |
|---|---|
A bis-pyridinium fullerene derivative induces apoptosis through the generation of ROS in BCR-ABL-positive leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Fullerenes; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Reactive Oxygen Species | 2022 |